Drug Type Antibody fusion proteins |
Synonyms BMS 986416, BMS-986416 |
Target |
Mechanism TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors), TGF-β3 inhibitors(Transforming growth factor beta 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 09 Aug 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | JP | 09 Aug 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | AR | 09 Aug 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | BE | 09 Aug 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 09 Aug 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CL | 09 Aug 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | NL | 09 Aug 2021 |